Samsung Biologics Acquires Human Genome Sciences Facility in Rockville, MD
Rockville, MD—Today, Korean contract development and manufacturing company Samsung Biologics announced that it will expand its U.S. manufacturing footprint through the strategic acquisition of the Human Genome Sciences facility in Rockville, Maryland from GSK. This acquisition, which is anticipated to close by the end of Q1 2026, represents Samsung Biologics’ first U.S.-based manufacturing site, cementing Montgomery County’s position as a premier destination for life sciences companies of all sizes.
Through the deal, the company will also retain more than 500 existing GSK employees at the site to ensure operational continuity and stability. The Rockville facility currently encompasses two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity supporting both clinical and commercial production. Existing products will continue to be manufactured at the site, and the company plans to upgrade technology and invest to expand the site’s capacity.
“The acquisition of GSK’s Rockville manufacturing campus by Samsung Biologics represents a significant achievement for Montgomery County,” said Montgomery County Executive Marc Elrich. “This $280 million investment brings the world’s largest contract drug manufacturer to Montgomery County, ensuring U.S.-based manufacturing continues, safeguarding over 500 current jobs, and setting the stage for further growth as Samsung boosts production capacity. It serves as a robust endorsement of the ecosystem we have cultivated, which is founded on talent, diversity, and enduring partnerships. We proudly welcome Samsung Biologics to Montgomery County, Maryland, and anticipate their contribution in enhancing our economy, workforce, and status as a global life sciences hub.”
“We are thrilled that Samsung Biologics has chosen to open its first U.S.-based manufacturing facility in Montgomery County,” said Jared Smith of the Montgomery County Economic Development Corporation. “This strategic acquisition reflects the strength of the life sciences sector, the depth of the talent pipeline, and the supportive business environment that exists in Montgomery County. We look forward to supporting them during this new phase of growth.”
The news of this investment not only preserves high-quality jobs in Montgomery County but
also strengthens the County’s position as a business destination for global life sciences
companies looking to innovate and scale in the United States.